Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland and premises in Dublin, Ireland and Bridgewater NJ, USA. Helsinn’s products are used in cancer supportive care, gastroenterology, and treatment of pain and inflammation. Its antiemetic product Aloxi, which is used to treat nausea and vomiting associated with chemotherapy, is the leading 5-HT3 antagonist in the US and Japanese markets.
With a unique business model, Helsinn in-licenses early to late stage new chemical entities, completing the entire R&D process including clinical studies, chemistry, manufacturing and controls, right through to the attainment of market approval world-wide. Then, the Group markets directly through its subsidiaries or out-licenses to its network of local pharmaceutical partners.
Since 2009 the Helsinn Group has invested over EUR 13 million, with the support of the Irish Development Authority (IDA), towards building up a Centre-of-excellence in Research and Development for Oral Solid Dosage forms at the Irish facility. Several projects are underway at the present time including a next generation product for treatment of Emesis, and a product to treat Cachexia associated with chemotherapy.